201 related articles for article (PubMed ID: 27664507)
1. Prediction of lung cancer incidence on the low-dose computed tomography arm of the National Lung Screening Trial: A dynamic Bayesian network.
Petousis P; Han SX; Aberle D; Bui AA
Artif Intell Med; 2016 Sep; 72():42-55. PubMed ID: 27664507
[TBL] [Abstract][Full Text] [Related]
2. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
3. Performance of the cancer risk management model lung cancer screening module.
Flanagan WM; Evans WK; Fitzgerald NR; Goffin JR; Miller AB; Wolfson MC
Health Rep; 2015 May; 26(5):11-8. PubMed ID: 25993046
[TBL] [Abstract][Full Text] [Related]
4. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
5. Lung cancer mortality reduction by LDCT screening-Results from the randomized German LUSI trial.
Becker N; Motsch E; Trotter A; Heussel CP; Dienemann H; Schnabel PA; Kauczor HU; Maldonado SG; Miller AB; Kaaks R; Delorme S
Int J Cancer; 2020 Mar; 146(6):1503-1513. PubMed ID: 31162856
[TBL] [Abstract][Full Text] [Related]
6. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Jonas DE; Reuland DS; Reddy SM; Nagle M; Clark SD; Weber RP; Enyioha C; Malo TL; Brenner AT; Armstrong C; Coker-Schwimmer M; Middleton JC; Voisin C; Harris RP
JAMA; 2021 Mar; 325(10):971-987. PubMed ID: 33687468
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study.
Criss SD; Cao P; Bastani M; Ten Haaf K; Chen Y; Sheehan DF; Blom EF; Toumazis I; Jeon J; de Koning HJ; Plevritis SK; Meza R; Kong CY
Ann Intern Med; 2019 Dec; 171(11):796-804. PubMed ID: 31683314
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated with a Positive Baseline Screening Exam Result in the National Lung Screening Trial.
Balekian AA; Tanner NT; Fisher JM; Silvestri GA; Gould MK
Ann Am Thorac Soc; 2016 Sep; 13(9):1568-74. PubMed ID: 27387658
[TBL] [Abstract][Full Text] [Related]
10. The Association between Smoking Abstinence and Mortality in the National Lung Screening Trial.
Tanner NT; Kanodra NM; Gebregziabher M; Payne E; Halbert CH; Warren GW; Egede LE; Silvestri GA
Am J Respir Crit Care Med; 2016 Mar; 193(5):534-41. PubMed ID: 26502000
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.
Infante M; Cavuto S; Lutman FR; Passera E; Chiarenza M; Chiesa G; Brambilla G; Angeli E; Aranzulla G; Chiti A; Scorsetti M; Navarria P; Cavina R; Ciccarelli M; Roncalli M; Destro A; Bottoni E; Voulaz E; Errico V; Ferraroli G; Finocchiaro G; Toschi L; Santoro A; Alloisio M;
Am J Respir Crit Care Med; 2015 May; 191(10):1166-75. PubMed ID: 25760561
[TBL] [Abstract][Full Text] [Related]
12. Overdiagnosis in low-dose computed tomography screening for lung cancer.
Patz EF; Pinsky P; Gatsonis C; Sicks JD; Kramer BS; Tammemägi MC; Chiles C; Black WC; Aberle DR;
JAMA Intern Med; 2014 Feb; 174(2):269-74. PubMed ID: 24322569
[TBL] [Abstract][Full Text] [Related]
13. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment.
Pinsky PF; Gierada DS; Black W; Munden R; Nath H; Aberle D; Kazerooni E
Ann Intern Med; 2015 Apr; 162(7):485-91. PubMed ID: 25664444
[TBL] [Abstract][Full Text] [Related]
14. Lung cancer screening using low-dose CT: the current national landscape.
Eberth JM; Qiu R; Adams SA; Salloum RG; Bell N; Arrington AK; Linder SK; Munden RF
Lung Cancer; 2014 Sep; 85(3):379-84. PubMed ID: 25088660
[TBL] [Abstract][Full Text] [Related]
15. Performance of lung cancer screening with low-dose CT in Gejiu, Yunnan: A population-based, screening cohort study.
Wei MN; Su Z; Wang JN; Gonzalez Mendez MJ; Yu XY; Liang H; Zhou QH; Fan YG; Qiao YL
Thorac Cancer; 2020 May; 11(5):1224-1232. PubMed ID: 32196998
[TBL] [Abstract][Full Text] [Related]
16. A simple model for predicting lung cancer occurrence in a lung cancer screening program: The Pittsburgh Predictor.
Wilson DO; Weissfeld J
Lung Cancer; 2015 Jul; 89(1):31-7. PubMed ID: 25863905
[TBL] [Abstract][Full Text] [Related]
17. National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population.
Pinsky PF; Gierada DS; Hocking W; Patz EF; Kramer BS
Ann Intern Med; 2014 Nov; 161(9):627-33. PubMed ID: 25199624
[TBL] [Abstract][Full Text] [Related]
18. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
[TBL] [Abstract][Full Text] [Related]
19. Modeling the impact of novel systemic treatments on lung cancer screening benefits.
Gogebakan KC; Lange J; Slatore CG; Etzioni R
Cancer; 2023 Jan; 129(2):226-234. PubMed ID: 36320180
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
